Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies

Affiliations

• ¹ Weill Cornell Medicine, Department of Medicine, New York.
• ² Moffitt Cancer Center, Tampa, FL.
• ³ Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD.
• ⁴ Swedish Cancer Institute, Seattle, WA.
• ⁵ Willamette Valley Cancer Institute/US Oncology, Eugene, OR.
• ⁶ MD Anderson Cancer Center, Houston, TX.
• ⁷ Moores Cancer Center, University of California San Diego, La Jolla, CA.
• ⁸ Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, CA.
• ⁹ Fred Hutchinson Cancer Research Center, Seattle, WA.
• ¹⁰ CLL Center, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
• ¹¹ Texas Oncology/US Oncology Research, Tyler, TX.
• ¹² Sunesis Pharmaceuticals, South San Francisco, CA.
• ¹³ Combs Consulting Service, Mountain View, CA.
• ¹⁴ CLL Center, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. jennifer_brown@dfci.harvard.edu.